Advertisement

BSX

Boston Scientific Corporation

Healthcare · USD

Set alert

Price alert · BSX

All alert types
41.98 USD -0.71 -1.66%
As of Oct 30, 2026 Extended hours 42.00 +0.05%
Bid
41.95 × 500
Ask
41.97 × 300
41.73 Day range 43.28
41.58 52-week range 104.98
YTD
-55.97%
1 year
-58.26%
Open
42.95
Prev close
42.69
Mkt cap
60.84B
Vol
22.47M
Avg vol
19.54M
EPS
2.37
P/E
17.71
Div yield
0.00%
More statistics
Low
41.73
High
43.28
Forward P/E
13.16
Beta
0.57
Short ratio
2.17
Inst. own
94.93%
Dividend
0.00
Ex-div date
Earnings
Feb 3, 2027
50-d avg
44.94
200-d avg
56.78
1y target
51.53

5D chart

Chart tools
Interval
BSX five-day price chart39.641.242.844.446.1Oct 26Oct 27Oct 28Oct 29Oct 30

Key statistics

Market cap
60.78B
Enterprise value
74.17B
Trailing P/E
17.70
Forward P/E
13.16
PEG ratio
0.60
Price / sales
2.88
Price / book
2.43
EPS (TTM)
2.37
Beta
0.57
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
16.62%
Revenue (TTM)
21.07B
Revenue growth
1.40%
Free cash flow
0
Total cash
539.00M
Total debt
12.62B
Return on equity
14.32%
Shares outstanding
1.45B
Short % of float
2.81%
50-day average
44.94
200-day average
56.78

Analyst view

Consensus: buy

Buy
Price target (mean) 51.53 +22.7% upside
Target (low)
41.00
Target (mean)
51.53
Target (high)
78.00
Ratings (0m) 31 20 buy · 11 hold · 0 sell
  • Strong buy6
  • Buy14
  • Hold11
  • Sell0
  • Strong sell0

Next earnings

Feb 3, 2027

Expected Feb 3, 2027. Consensus EPS estimate 0.7756.

Earnings history

Financials — quick view

All financials
BSX Revenue — quarterly 5.44B
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
BSX Net income — quarterly 907.00M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
BSX EPS — quarterly 0.62
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

BSX recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 3, 2027Dec 30, 20260.79———
Oct 28, 2026Sep 30, 20260.7270.730.00+0.41%
Jul 29, 2026Jun 30, 20260.8350.86+0.03+2.99%
Apr 22, 2026Mar 31, 20260.7880.80+0.01+1.52%
Feb 4, 2026Dec 31, 20250.7810.80+0.02+2.43%
Oct 22, 2025Sep 30, 20250.7140.75+0.04+5.04%

Upgrades / downgrades

BSX analyst upgrades and downgrades
DateFirmActionFromTo
Oct 30, 2026TD CowendownBuyHold
Oct 30, 2026BarclaysmainEqual-WeightEqual-Weight
Oct 29, 2026JefferiesdownBuyHold
Oct 29, 2026Canaccord GenuitymainBuyBuy
Oct 29, 2026BernsteinmainOutperformOutperform
Oct 29, 2026RBC CapitalmainOutperformOutperform

About Boston Scientific Corporation

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Sector
Healthcare
Industry
Medical Devices
Country
United States

News

Your note

Sign in to keep a note on BSX — it syncs with the Stock Master app.

Insider holders

BSX insider holders
InsiderRelationLatest transactionDateShares held
BRENNAN DANIEL JChief Financial OfficerSaleFeb 18, 2025225,808
BROWN VANCE RGeneral CounselStock Award(Grant)Feb 12, 202654,244
BUTCHER ARTHUR COfficerConversion of Exercise of derivative securityApr 30, 202677,115
CARRUTHERS WENDYOfficerSaleDec 1, 202429,308
FITZGERALD JOSEPH MICHAELOfficerStock Award(Grant)Feb 12, 2026219,141
LUDWIG EDWARD J.DirectorPurchaseJul 30, 202630,359

Institution ownership

BSX institution ownership
Holder% heldSharesValueReported
Blackrock Inc.8.95%129,680,9165.44BJun 29, 2026
Vanguard Capital Management LLC6.70%97,087,5534.07BJun 29, 2026
State Street Corporation4.84%70,111,1962.94BJun 29, 2026
Primecap Management Company3.49%50,520,9142.12BJun 29, 2026
FMR, LLC3.15%45,702,8451.92BJun 29, 2026
Geode Capital Management, LLC2.31%33,440,1021.40BJun 29, 2026

Fund ownership

BSX fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.26%47,181,2841.98BJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard 500 Index Fund2.66%38,518,7881.62BJun 29, 2026
VANGUARD CHESTER FUNDS-Vanguard PRIMECAP Fund2.13%30,831,0391.29BJun 29, 2026
Fidelity Concord Street Trust-Fidelity 500 Index Fund1.33%19,294,226809.20MAug 30, 2026
iShares Trust-iShares Core S&P 500 ETF1.33%19,310,588809.89MSep 29, 2026
SPDR S&P 500 ETF TRUST-State Street SPDR S&P 500 ETF Trust1.23%17,894,864750.51MSep 29, 2026
Advertisement